Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis: post-hoc analysis from the phase III, double-blind, placebo- and active-comparator–controlled VOYAGE 1/2 trials
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis: post-hoc analysis from the phase III, double-blind, placebo- and active-comparator–controlled VOYAGE 1/2 trials
Authors
Keywords
-
Journal
JOURNAL OF DERMATOLOGICAL TREATMENT
Volume -, Issue -, Pages 1-7
Publisher
Informa UK Limited
Online
2020-05-18
DOI
10.1080/09546634.2020.1770174
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Consistent responses with guselkumab treatment in Asian and non‐Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2
- (2019) Kristian Reich et al. JOURNAL OF DERMATOLOGY
- Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3
- (2018) Lajos Kemény et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study
- (2018) Mamitaro Ohtsuki et al. JOURNAL OF DERMATOLOGY
- Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
- (2018) Kenneth B Gordon et al. LANCET
- Epidemiology and cardiovascular comorbidities in patients with psoriasis: A Korean nationwide population-based cohort study
- (2017) Eui Hyun Oh et al. JOURNAL OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Epidemiology of psoriatic disease and current treatment patterns from 2003 to 2013: A nationwide, population-based observational study in Taiwan
- (2016) Ting-Shun Wang et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets
- (2016) Jaehwan Kim et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- A systematic review of worldwide epidemiology of psoriasis
- (2016) I.M. Michalek et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
- (2016) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety of Conventional Systemic Agents and Biologic Agents in the Treatment of Psoriasis
- (2015) Robert Bissonnette et al. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
- Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
- (2014) Howard Sofen et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study
- (2014) Mamitaro Ohtsuki et al. JOURNAL OF DERMATOLOGY
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)
- (2011) Tsen-Fang Tsai et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Psoriasis
- (2009) Frank O. Nestle et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started